Indicator, Reagent, or Diagnostic Aid – Page 2

GE HealthCare’s Flyrcado (flurpiridaz F 18) PET Radiotracer Receives FDA Approval for Enhanced Detection of Coronary Artery Disease

10 months ago talkbio0Tagged Approved, Cardiac imaging, Coronary Arteriosclerosis, F 18, Flyrcado, Health care facility, nuclear cardiology, Pet Animal, Radiotracers, United States Food and Drug Administration

GE HealthCare, Flyrcado, flurpiridaz F 18, PET radiotracer, Coronary artery disease (CAD), FDA approval, Cardiac imaging, Nuclear cardiology

Telix Acquires RLS to Bolster Radiopharmaceutical Manufacturing and Distribution in North America

10 months ago talkbio0Tagged Acquisition (action), North America, production, radiometal, Radiopharmaceuticals, Restless Legs Syndrome, Social Networks, Spatial Distribution, Telix

Telix Pharmaceuticals, RLS (USA) Inc., radiopharmaceutical manufacturing, distribution, acquisition, North America, radiometal production network

ITM Secures Exclusive Global License for Debiopharm’s CA IX-Targeted Theranostic Pair

11 months ago talkbio0Tagged CA9 gene, Debiopharm, Malignant Neoplasms, Radiopharmaceuticals, SLC22A18 gene, Solid Neoplasm, Theranostic Pair

ITM, Debiopharm, CA IX, Theranostic Pair, Radiopharmaceutical, Solid Tumors, Cancer Treatment

Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance

11 months ago talkbio0Tagged AlphaMedix, Cancer Therapeutic Procedure, Drug Industry, Neoplasms, Neurosecretory Systems, Novartis, radioligand therapy, Radiopharmaceuticals, sanofi

Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry

Sanofi Enters Radiopharmaceutical Market with $110 Million Licensing Agreement

11 months ago talkbio0Tagged AlphaMedix, Multiple Epiphyseal Dysplasia, Neoplasms, Neurosecretory Systems, RadioMedix, Radiopharmaceuticals, sanofi

Sanofi, Radiopharmaceuticals, Licensing Deal, RadioMedix, Orano Med, AlphaMedix, Neuroendocrine Tumors

Voyager Therapeutics Secures $100M Upfront Payment in Expanded Gene Therapy Partnership with Novartis

11 months ago talkbio0Tagged Biotechnology, capsid discovery, gene therapy, Huntington Disease, Novartis, Spinal Muscular Atrophy, Tracer

Gene therapy, Novartis, Voyager Therapeutics, Huntington’s disease, Spinal muscular atrophy (SMA), TRACER capsid discovery platform, Biotechnology collaboration

Merck’s WINREVAIR Receives EU Approval for Pulmonary Arterial Hypertension Treatment

11 months ago talkbio0Tagged 4-aminohippuric acid, Approved, EU, Merck, Pulmonary arterial hypertension, Winrevair

WINREVAIR, Merck, EU Approval, Pulmonary Arterial Hypertension, PAH Treatment

Siemens Healthineers Expands into Europe with Acquisition of Novartis’ Radiodiagnostic Manufacturing Network

11 months ago talkbio0Tagged Acquisition (action), Europe, Novartis, Pet Animal, Radiodiagnostic Manufacturing Network, Radiopharmaceuticals, Siemens Healthineers

Siemens Healthineers, Novartis, Acquisition, Radiodiagnostic Manufacturing Network, Europe, PET Radiopharmaceuticals

Liquidia’s Yutrepia Receives Tentative FDA Approval Due to Tyvaso Exclusivity

11 months ago talkbio0Tagged 4-aminohippuric acid, exclusivity, Liquidia, PH-ILD, Pulmonary arterial hypertension, Tentative Approval, Tyvaso, United States Food and Drug Administration, YUTREPIA

Liquidia, Yutrepia, FDA, tentative approval, Tyvaso, exclusivity, pulmonary arterial hypertension, PAH, PH-ILD

Actinium’s Radioconjugate Faces Setback as FDA Requests New Study

12 months ago talkbio0Tagged Actinium, Cancer Therapeutic Procedure, Clinical Research, Iomab-B, Radioconjugate, Regulatory Affairs, United States Food and Drug Administration

Actinium Pharmaceuticals, radioconjugate, FDA, new study, Iomab-B, regulatory affairs, biotech, cancer treatment